#efta02681674
LightNews LightNews
epsteinweb.bsky.social
Parts 1-2/2 — EFTA02681674.jpg
#epsteinweb #efta02681674
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA02681671 | EFTA02681674 Applied Viruses - Please do not redistribute. Contact: Alexandra Treschow Competitors There are external competitors in the synthetic biology and virological fields. Synthetic biology: Synthetic genomics, Intrexon, Ginkgo Bioworks, BIOFAB (also an ally) Oncolytics: Amgen, Jennerex, Oncolytics Biotech, Oncos Therapeutics, Genelux Phage Therapy: Phage Biotech Ltd., Pherecydes Pharma, Lisando, Micreos Patents and Licenses • We do not expect to file patents at this time but will review this position once virus assembly line is operational. • The reference genomes for the viruses we will engineer are in the public domain and available online at the National Center for Biotechnology Information (NCBI). • Our commercial success depend on in part on not infringing the patents and property rights of others. We will keep up to date on our freedom to operate and competing intellectual properties for technology, manufacturing and product portfolios. • Open source viral engineering components available at MIT Registry of Standard Biological Parts and are suitable for proof-of-concept development. • Derivative viral works will become trade secrets of Applied Viruses or released under creative commons license. • We will create a formal licensing relationship with Genome Compiler Corporation, on whose platform we expect to develop our initial software tools. The Synbiota open source platform is an alternative. • We have an exclusive relationship with Pink Army Cooperative. • Potential for key partnerships with Karolinska Institute, SALSS, Singularity University, Autodesk, Inc., Halcyon Molecular (DNA sequencing), Cambrian genomics (Genome synthesis), Organovo (Tissue engineering), Aura Biosciences (Nanoparticle delivery systems), and more. Risks Synthetic biology represents a paradigm shift in genetic engineering and biotechnology. Legacy regulatory and intellectual property architectures are the largest barriers to our success. Current Team 1. Alexandra Treschow, PhD. Responsiblities: CEO/CSO 2. Bjorn Hamberg, MBA, CEO, Alfta Rehab, Responsibilities: Finance and Operations 3. Gerard Ponce de Leon, MBA, Responsibilities, Sales, Business Development, Partnerships 4. Andrew Hessel, MSc, Co-chair Bioinformatics and Biotechnology at Singularity University. Responsibilities: Strategic planning The team will be expanded over the next few months, adding deep expertise in virology and microbiology, DNA sequencing and bioinformatics, regulatory and legal affairs, web and database development, laboratory automation, social networking and marketing, and sales. 4 of 5 EFTA_R1_01993297 EFTA02681674 Epstein Web iOS app on the App Store.
April 18, 2026 at 2:04 AM